International validation of the EORTC QLQ‐CLL17 questionnaire for assessment of health‐related quality of life for patients with chronic lymphocytic leukaemia
Oerlemans,Simone Efficace,Fabio Kieffer,Jacobien M. Kyriakou,Charalampia Xochelli,Aliki Levedahl,Kerstin Petranovic,Duska Borges,Fabio Cardoso Bredart,Anne Shamieh,Omar
Oerlemans,Simone
Efficace,Fabio
Kieffer,Jacobien M.
Kyriakou,Charalampia
Xochelli,Aliki
Levedahl,Kerstin
Petranovic,Duska
Borges,Fabio Cardoso
Bredart,Anne
Shamieh,Omar
Abstract
Selecting the most appropriate chronic lymphocytic leukaemia (CLL) treatment is challenging. Patient-reported health-related quality of life (HRQoL) is therefore a critical aspect to consider. This international study by the European Organization for Research and Treatment of Cancer (EORTC) tested the psychometric properties of a newly developed measure for CLL patients: the EORTC QLQ-CLL17 to supplement the core questionnaire (EORTC QLQ-C30). Patients with CLL (n = 341) from 12 countries completed the QLQ-C30, QLQ-CLL17 and a debriefing questionnaire. Sociodemographic and clinical data were recorded from medical records. A high percentage (30%-66%) reported symptoms and/or worries (e.g. aches/pains in muscles, lack of energy and worry/fears about health). Confirmatory factor analysis showed an acceptable to good fit of the 17 items on the three scales (i.e. symptom burden, physical condition/fatigue and worries/fears about health and functioning). Completion took on average 8 min. Test-retest and convergent validity was demonstrated. The QLQ-CLL17 differentiated between patients with an Eastern Cooperative Oncology group (ECOG) performance of 0 versus 1-3 (p's < 0.01 and clinically relevant). The newly developed EORTC QLQ-CLL17 will increase sensitivity of HRQoL assessment in patients with CLL. Implementation of this questionnaire both in clinical research and practice will help to generate unique clinically relevant data to better inform CLL treatment decision-making.
Description
The project was allocated an EORTC Quality of Life Group (QLG) grant for module development, Phase IV
Date
2022
Journal Title
Journal ISSN
Volume Title
Publisher
Research Projects
Organizational Units
Journal Issue
Keywords
CHLORAMBUCIL, CRITERIA, EORTC, FEAR, LYMPHOMA, PRO, QLQ-C30, REPORTED OUTCOMES, RITUXIMAB, THERAPY, TRIALS, chronic lymphocytic leukaemia, psychometric properties, quality of life, questionnaire, symptoms, SDG 3 - Good Health and Well-being
Citation
Oerlemans, S, Efficace, F, Kieffer, J M, Kyriakou, C, Xochelli, A, Levedahl, K, Petranovic, D, Borges, F C, Bredart, A, Shamieh, O, Gziskevicius, L, Lehmann, J, Scholz, C W, Caocci, G, Molica, S, Stamatopoulos, K, Panteliadou, A, Papaioannou, M, Alrjoob, W, Baliakas, P, Rosenquist, R, Malak, S, Miranda, A, Cocks, K & van de Poll‐Franse, L 2022, 'International validation of the EORTC QLQ‐CLL17 questionnaire for assessment of health‐related quality of life for patients with chronic lymphocytic leukaemia', British Journal of Haematology, vol. 197, no. 4, pp. 431-441. https://doi.org/10.1111/bjh.18072